Nanotechnology Now - Press Release: NanoMed Pharmaceuticals Hires Chief Scientific Officer

Home > Press > NanoMed Pharmaceuticals Hires Chief Scientific Officer

Abstract:
NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has hired Harry C. Ledebur, Jr., PhD. to serve as the company's Vice President Research & Development, Chief Scientific Officer. Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations & Scientific Affairs for Chromos Molecular Systems, Inc. where he was a member of Chromos' Executive Committee and was responsible for all discovery and product development programs along with quality systems, regulatory affairs and site operations.

NanoMed Pharmaceuticals Hires Chief Scientific Officer

Kalamazoo, MI | Posted on June 21st, 2007

"I am extremely pleased to have the opportunity to partner with a
research and development executive of Harry's caliber," said Stephen
Benoit, NanoMed's President and CEO. "His extensive experience in
preclinical discovery research, product and business development within the
biotechnology and pharmaceutical industries should prove to be a tremendous
asset to NanoMed as we build our drug pipeline and forge strategic product
development relationships," Benoit added. NanoMed's lead product is a
nanoparticle formulation of an FDA-approved cancer drug used to treat
adults diagnosed with acute myeloid leukemia. This lead product is expected
to enter human clinical trials in 2008.

"NanoMed is an exciting company with an innovative nanotechnology
platform for the rapid development of a diversified portfolio of
therapeutic and diagnostic products," said Dr. Ledebur. "I am thrilled to
be joining the NanoMed team and to be given the opportunity to bring
NanoMed's products to market while helping to build a sustainable specialty
pharmaceutical company," Ledebur added.

Previously, Dr. Ledebur was Vice President of Research & Development
and Discovery Programs for Caprion Pharmaceuticals Inc., as well as Program
Head of the Antigen Presenting Cell Program at US-based Valentis, Inc.
(formerly GeneMedicine, Inc.). He began his career at Boehringer Ingelheim
Pharmaceuticals Inc. Dr. Ledebur received his Ph.D. in Molecular & Cell
Biology from Pennsylvania State University and his B.Sc. in Biochemistry
from The Ohio State University.

####

About NanoMed Pharmaceuticals, Inc.
NanoMed Pharmaceuticals(R), Inc. ( http://www.nanomedpharm.com ) is an
early-stage specialty pharmaceutical company dedicated to developing
improved therapeutic and diagnostic products to treat or detect cancer and
other serious diseases. The company's lead product is a nanoparticle
formulation of an FDA-approved cancer drug used to treat adults diagnosed
with acute myeloid leukemia. This lead product is being developed using
Nanotemplate Engineering(TM), the company's proprietary nanoparticle
manufacturing technology used to formulate small molecules, peptides,
proteins, plasmid DNA, and diagnostic agents. NanoMed is headquartered in
Kalamazoo, Michigan.

For more information, please click here

Contacts:
Stephen Benoit
President & CEO

NanoMed Pharmaceuticals, Inc.
7107 Elm Valley Drive, Room B1210
Kalamazoo, Michigan 49009 USA
T - (269) 488-8525
F - (269) 488-8544

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: